GU Cancers 2021 | PD1/L1 inhibitors with ACEIs and ARBs improves tumor regression for mUC
Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a retrospective analysis investigating the impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC). The study analyzed data from 178 patients with mUC who had received PD1/L1 inhibitor therapy. The results demonstrated that patients who had received angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) had greater tumor regression and improved overall survival (OS). This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Dr Guru Sonpavde, MD, has participated in advisory boards for BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, AstraZeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Immunomedics/Gilead, Scholar Rock and G1 Therapeutics; has received research support from Sanofi, AstraZeneca, Immunomedics/Gilead, QED, Predicine and BMS; has had travel costs reimbursed by BMS and AstraZeneca; has received speakers fees from Physicians Education Resource (PER), Onclive, Research to Practice and Medscape; has received writing fees from Uptodate and is Editor of Elsevier Practice Update Bladder Cancer Center of Excellence; and has participated in unpaid steering committees of trials or studies with BMS, Bavarian Nordic, Seattle Genetics, QED, G1 Therapeutics, and in paid steering committees of trials or studies with AstraZeneca, EMD Serono and Debiopharm.
